An Update on Neuralstem’s Phase I Trial

Dr. Eva Feldman, principle investigator of the Neuaralstem Phase I clinical trial, presented an update about the trial results on October 8at the American Neurological Association annual meeting in Boston, MA. Neuralstem’s Phase I trial is to test the safety of the NSI-566 spinal cord stem cells for the treatment of ALS. So far, 15 people have been treated and three of the 15 have received two treatments. The Phase I part of the trail is set to conclude six months after the last patient was treated in August. Dr. Feldman said that “this has been a very successful trial so far. We have demonstrated that intraspinal transplantation is feasible and well-tolerated. Although this phase of the trial was not powered to demonstrate efficacy, we appear to have interrupted the progression of the disease in one subgroup of patients. We are anxious to move to future trial phases to examine therapeutic efficacy.”

Click here to read more.

Share this: